艾曲泊帕联合脉冲地塞米松一线治疗免疫性血小板减少症的安全性与疗效
本研究评估艾曲泊帕联合脉冲地塞米松作为免疫性血小板减少症(ITP)一线治疗,能否提高患者长期维持血小板>50×10^9/L且无需进一步治疗的比例。
要点
- 停药6个月中位血小板为158×10^9/L,最长维持超过3年。
- 所有患者耐受良好,未报告3级及以上不良事件。
核心结论
- 艾曲泊帕联合脉冲地塞米松一线治疗可使相当比例ITP患者获得停药后持久应答。
研究设计与样本
- 治疗方案为艾曲泊帕25-75 mg每日根据血小板反应调整用12周,联合地塞米松40 mg每日连续4天、每4周1次、共1-3疗程。
主要发现
- 停药随访6个月时中位血小板计数为158×10^9/L。
- 26例应答者中仅2例分别在8个月和9个月随访时复发,其余24例仍维持血小板>50×10^9/L,最长超过3年。
- 所有患者耐受良好,未报告3级及以上不良事件。
关键数值与推荐
- 主要终点为无进一步ITP治疗情况下维持血小板>50×10^9/L超过6个月的持久应答。
- 艾曲泊帕剂量为25-75 mg每日,根据地塞米松为40 mg每日连续4天、每4周1次、共1-3疗程。
临床怎么用
- 对于初治ITP患者,可考虑艾曲泊帕联合脉冲地塞米松作为一线治疗以提高持久停药应答。
- 治疗期间根据血小板反应调整艾曲泊帕剂量,地塞米松采用脉冲给药。
局限性
- 研究为单臂设计,样本量较小(50例入组,46例可评估),缺乏对照组。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Current first-line treatments for immune thrombocytopenia (ITP) usually have transient effects and sustained platelet response off therapy remains low. We evaluated whether eltrombopag plus pulsed dexamethasone as first-line therapy can increase the proportion of patients maintaining platelet counts >50 × 109 /l for a prolonged period without further ITP therapy. Treatment consisted of eltrombopag 25-75 mg daily according to platelet response for 12 weeks plus dexamethasone, 40 mg daily for four consecutive days every four weeks for 1-3 courses. Primary endpoint was durable response off therapy defined as maintaining platelet counts >50 × 109 /l for more than six months without further ITP therapy. Fifty ITP subjects were enrolled between November 2014 and March 2019. Out of 46 evaluable subjects, 26 (56·5%) had achieved the primary endpoint. The median platelet counts at six months off-treatment follow-up were 158 × 109 /l. Only two out of 26 responders had relapsed at eight- and nine-month follow-up. The remaining 24 are still maintaining platelet counts >50 × 109 /l, the longest over three years. All subjects tolerated treatment well and no Grade 3 or above adverse effects were reported. Eltrombopag plus pulsed dexamethasone as a first-line therapy could result in durable response off therapy in a significant number of ITP subjects.
引用
- Zhang L, Zhang M, Du X, et al. Safety and efficacy of eltrombopag plus pulsed dexamethasone as first-line therapy for immune thrombocytopenia. Br J Haematol. 2020. PMID: 31943136. doi:10.1111/bjh.16327
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。